The strategies involved in the development of therapeutics for neurodegenerative disorders
are very complex and challenging due to the existence of the blood-brain barrier (BBB), a …

Clinical trial results presented in 2019 suggest that antibody-based removal of cerebral
amyloid β (Aβ) plaques may possibly clear tau tangles and modestly slow cognitive decline …

Drug repositioning and repurposing can enhance traditional drug development efforts and
could accelerate the identification of new treatments for individuals with Alzheimer disease …

Abstract Alzheimer's disease (AD), the most common neurodegenerative disorder, is
characterized by memory loss and cognitive dysfunction. The accumulation of misfolded …

Background Alzheimer's disease (AD) is a devastating neurodegenerative disease leading
to dementia. The field has made significant progress over the last 15 years. AD diagnosis …

Current therapeutic strategies for Alzheimer's disease (AD) treatments mainly focus on β‐
amyloid (Aβ) targeting. However, such therapeutic strategies have limited clinical outcomes …

Investigations of Alzheimer's disease (AD), traumatic brain injury (TBI), and related brain
disorders have provided extensive evidence for involvement of cathepsin B, a lysosomal …

The potential benefit of the anti‐amyloid drug aducanumab based on results of recent
EMERGE and ENGAGE clinical trials has generated great controversy and has very …

The marine natural product fucoxanthin has been reported previously to produce anti-
Alzheimer's disease (AD) neuroprotective effects in vitro and in vivo. Fucoxanthin was also …

Alzheimer's disease (AD) is a progressive neurodegenerative disease manifested by
cognitive impairment. As a unique approach to open the blood-brain barrier (BBB) …